NEW YORK (GenomeWeb) – Agilent Technologies announced today that it is extending a longstanding agreement with PerkinElmer to continue the supply of chips for Agilent's 2100 Bioanalyzer system.
The terms of the deal extension were not disclosed.
The 2100 Bioanalyzer, which was first introduced in 1999, is used in DNA sequencing, gene expression research, DNA fragment analysis, and quality control for protein-based drugs, among other applications, according to Agilent.
"This agreement ensures that, for years to come, molecular biologists can continue to depend on the sample quality and high-fidelity data they obtain with the Agilent 2100 Bioanalyzer system," Knut Wintergerst, marketing and support manager for microfluidics at Agilent, said in a statement.